Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new analysis of data from two clinical trials indicated that treprostinil (Remodulin) in addition to existing treatment was safe and effective in preventing clinical worsening for these patients.
top of page
Recent Posts
The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial...
Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size...
The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...
bottom of page
Comments